Clinics and Research in Recurrent Hepatocellular Carcinoma

Dear Colleagues,

Recurrent hepatocellular carcinoma (rHCC) after primary treatment is high in most patients and often results in a life-threatening situation. The recurrence rates after primary hepatectomy are around 70% or higher within 5 years, usually after resection. Up to this moment, a precise treatment strategy for rHCC, including surgical or non-surgical methods, has remained controversial. Its high recurrence rate has consistently undermined patients’ survival, making rHCC a major global healthcare problem. The incidence rates were high in East Asia (China, Korea, and Vietnam) and Sub-Saharan Africa. About three-quarters of liver cancer patients occur in Asia, especially in China, accounting for more than half of the world’s burden; in reality, liver cancer is still a worldwide health issue. A total of 841,000 (4.7%) new HCC patients were estimated, and another 782,000 (8.2%) HCC-related deaths were reported, globally in 2018. The surveillance, early diagnosis, and treatment of rHCC are needed in most institutes. An enhanced understanding of this Special Issue can be obtained by reading the applicable portions from the experts around the world. In addition, more detailed information may be found in the associated documents related to clinically important aspects of rHCC.

This Special Issue aims to provide precise surveillance and treatment strategies for recurrent hepatocellular carcinoma (rHCC). The scope of this Special Issue is based on Eastern and Western studies; recurrence after surgical or non-surgical treatments is common and life-threatening. In order to improved survival, the option of a re-treatment method and basic hepatocarcinogenesis should be established where possible.

In this Special Issue, original research articles and reviews are welcome.

I look forward to receiving your contributions.

Dr. Chen-Guo Ker
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatocarcinogenesis
• hepatocellular carcinoma
• recurrence
• hepatectomy
• liver transplantation
• radiofrequence ablation
• transhepatic artery chemoembolization
• radiotherapy
• target therapy
• immunotherapy